TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23116088

Group type: EXPERIMENTAL
Intervention: Staff training plus a screening and referral protocol
Number of subjects: 216

Group type: COMPARATOR
Intervention: Staff training
Number of subjects: 216

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 216
Study: 22136096

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 65

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 65
Study: 18365893

Group type: EXPERIMENTAL
Intervention: High intensity exercise (80-90% of VO(2peak))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Moderate intensity exercise (50-60% of VO(2peak))
Number of subjects: 17
Study: 17057389

Group type: EXPERIMENTAL
Intervention: Iscador therapy (mistletoe preparation)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no mistletoe therapy)
Number of subjects: 122
Study: 12776030

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 10653230

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colectomy (LAC)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Open segmental colectomy (OC)
Number of subjects: 255
Study: 9100997

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 50 mg bromfenac
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral administration of 50 mg bromfenac
Number of subjects: 12
Study: 8263444

Group type: EXPERIMENTAL
Intervention: Injections given inside the mental foramen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Injections given outside the mental foramen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Injections given inside or outside the mental foramen
Number of subjects: 30
Study: 7235209

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study: 31688620

Group type: EXPERIMENTAL
Intervention: Hydroxyurea ordered by residents after policy change
Number of subjects: 209

Group type: COMPARATOR
Intervention: Hydroxyurea ordered by residents before policy change
Number of subjects: 209
Study: 30334340

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 64
Study: 28758802

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 897

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg
Number of subjects: 897
Study: 26088759

Group type: EXPERIMENTAL
Intervention: Protocol-based early goal-directed therapy (EGDT)
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Protocol-based standard therapy
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Protocol-based therapy (EGDT and standard therapy combined)
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Protocol-based EGDT
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1351
Study: 24145346

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m²) plus carboplatin (AUC 6) plus bevacizumab (15 mg/kg) followed by maintenance pemetrexed plus bevacizumab (PemCBev)
Number of subjects: 939

Group type: COMPARATOR
Intervention: Paclitaxel (200 mg/m²) plus carboplatin (AUC 6) plus bevacizumab (15 mg/kg) followed by maintenance bevacizumab (PacCBev)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus bevacizumab (PemCBev)
Number of subjects: 939

Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin plus bevacizumab (PacCBev)
Number of subjects: 939
Study: 21326612

Group type: EXPERIMENTAL
Intervention: Reliably predictable rewards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less predictable rewards
Number of subjects: 0
Study: 19647206

Group type: EXPERIMENTAL
Intervention: Individualised homeopathic medicines (6C potency, oral liquid, two doses at baseline and 12 hours later)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17223865

Group type: EXPERIMENTAL
Intervention: Rambazole, 1 mg, once daily for 8 weeks
Number of subjects: 6
Study: 17151582

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 20
Study: 12719848

Group type: EXPERIMENTAL
Intervention: Surgery performed at night (after 9 p.m.)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Surgery performed during the day
Number of subjects: 170
Study: 10357731

Group type: EXPERIMENTAL
Intervention: Butter meal (100 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olive oil meal (80 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control meal (energy-free soup with 50 g carbohydrate)
Number of subjects: 10
Study: 7675971

Group type: EXPERIMENTAL
Intervention: SSRI-RIMA combination treatment (fluvoxamine and moclobemide)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SSRI monotherapy (fluvoxamine only)
Number of subjects: 18
Study: 1971539

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 18
Study: 7082023

Group type: EXPERIMENTAL
Intervention: Infrared radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heat administered before or after UV exposure
Number of subjects: 0
Study: 31218938

Group type: EXPERIMENTAL
Intervention: Quantitative MRI measurements of multifidus muscle signal intensity
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Qualitative MRI grading of multifidus muscle fat content
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Correlation analysis between fat content and severity of nerve compression
Number of subjects: 90
Study: 28477497

Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI) anhedonia subscale
Number of subjects: 0
Study: 26359750

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) plus Specialist Medical Care (SMC)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET) plus Specialist Medical Care (SMC)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT) plus Specialist Medical Care (SMC)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC) alone
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET) vs Adaptive Pacing Therapy (APT)
Number of subjects: 641
Study: 23881677

Group type: EXPERIMENTAL
Intervention: ADD diet with chelated trace minerals, organic selenium yeast, direct-fed microbials, and Yucca schidigera extract
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ADD diet with organic selenium yeast
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ADD diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: CTRL diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Feces stockpiled to simulate a crude composting method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Feces stockpile temperature
Number of subjects: 10
Study: 22108275

Group type: EXPERIMENTAL
Intervention: Maximal tolerable dose of valsartan (up to 320 mg/day)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Usual dose of valsartan (80 mg/day)
Number of subjects: 1116
Study: 18516718

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16581685

Group type: EXPERIMENTAL
Intervention: Red LED therapy (20 min, 96 J/cm2, 633 nm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unirradiated control
Number of subjects: 10
Study: 14529770

Group type: EXPERIMENTAL
Intervention: Induction therapy with cisplatin (20 mg/m(2)) and twice-daily accelerated irradiation (1.8 Gy to pelvis, 1.6 Gy to tumor)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with MCV (methotrexate, cisplatin, vinblastine)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Induction and consolidation chemotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Induction and consolidation RT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall survival, bladder-intact survival, locoregional failure, distant metastasis
Number of subjects: 52
Study: 10980253

Group type: EXPERIMENTAL
Intervention: Social contract theory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hazard management theory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relevance theory
Number of subjects: 0
Study: 8629680

Group type: EXPERIMENTAL
Intervention: Benzodiazepine treatment (clonazepam, alprazolam, or other benzodiazepines)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Clonazepam nightly
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Chronic alprazolam treatment and other benzodiazepine treatments
Number of subjects: 170
Study: 1457360

Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CAFt: cyclophosphamide 500 mg m‐2 + doxorubicin 40 mg/m‐2 + ftorafur 20 mg kg‐1 orally day 1‐14)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy and adjuvant chemotherapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Postoperative radiation, adjuvant chemotherapy and tamoxifen (40 mg daily for 2 years)
Number of subjects: 200
Study: 6373547

Group type: EXPERIMENTAL
Intervention: Propranolol (twice daily at doses that reduced resting heart rate by 25%)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 74
Study: 30160086

Group type: EXPERIMENTAL
Intervention: Low-volume plyometric training group (LPG=10 participants)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-volume plyometric training group (HPG=11 participants)
Number of subjects: 21
Study: 29415330

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10^9 colony-forming units) taken daily by mothers from 14-16 weeks of gestation until 6 months post-partum if breastfeeding
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (mother and child intervention)
Number of subjects: 423
Study: 26966087

Group type: EXPERIMENTAL
Intervention: Straight cannula group (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Angled cannula group (n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 24678937

Group type: EXPERIMENTAL
Intervention: TAVR with self-expanding transcatheter valve
Number of subjects: 795

Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 795
Study: 22935444

Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 2388

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 2388
Study: 19735984

Group type: EXPERIMENTAL
Intervention: Cycling women (late luteal phase)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with estradiol serum concentrations in the cycling range
Number of subjects: 84

Group type: COMPARATOR
Intervention: Postmenopausal women with HRT
Number of subjects: 84

Group type: COMPARATOR
Intervention: Postmenopausal women without HRT
Number of subjects: 84
Study: 17065180

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg thrice daily for 72 hours starting 48 hours before the procedure
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (isotonic saline infusion only)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) and isotonic saline infusion
Number of subjects: 82
Study: 15862720

Group type: EXPERIMENTAL
Intervention: Increased water intake
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 141
Study: 11313831

Group type: EXPERIMENTAL
Intervention: IC351 (Cialis) 2 mg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: IC351 (Cialis) 5 mg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: IC351 (Cialis) 10 mg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: IC351 (Cialis) 25 mg
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 9461707

Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 46
Study: 7949227

Group type: EXPERIMENTAL
Intervention: HLA-DQA1 and HLA-DQB1 gene alleles
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: DQA1 and DQB1 gene alleles
Number of subjects: 234
Study: 3356771

Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31664719

Group type: EXPERIMENTAL
Intervention: Quilting closure (Q)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Simple continuous apposition (SC)
Number of subjects: 297

Group type: COMPARATOR
Intervention: No subcutaneous closure (NC)
Number of subjects: 297
Study: 30170401

Group type: EXPERIMENTAL
Intervention: Group A (OA specimens)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group D (RA specimens with cement)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group C (OA specimens with cement)
Number of subjects: 80
Study: 27159505

Group type: EXPERIMENTAL
Intervention: Rifapentine (approximately 7.5 mg/kg) plus moxifloxacin
Number of subjects: 121

Group type: COMPARATOR
Intervention: Rifampin (approximately 10 mg/kg) plus ethambutol
Number of subjects: 121
Study: 26232684

Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 116
Study: 23902889

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 180
Study: 20196977

Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine capsules (ERCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate-release carbamazepine (IR)
Number of subjects: 0
Study: 18221532

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/day
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 16755150

Group type: EXPERIMENTAL
Intervention: Doxazosin 1 mg/day (increased to 2 mg/day and 4 mg/day) with a beta-blocker added after 1 month if needed
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (continued treatment as per enrollment)
Number of subjects: 600
Study: 14584381

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) combined with a single dose of artesunate (AS)
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1375
Study: 10486449

Group type: EXPERIMENTAL
Intervention: CPR-Video
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: CPR-Didactic
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: CPR-Social Support
Number of subjects: 578

Group type: COMPARATOR
Intervention: Control (no CPR training)
Number of subjects: 578
Study: 8759069

Group type: EXPERIMENTAL
Intervention: Poloxamer 188 (RheothRx) infusion for 48 hours
Number of subjects: 114
Study: 1759572

Group type: EXPERIMENTAL
Intervention: Defibrinogenation (DF) therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Betamethasone (BM) therapy
Number of subjects: 168
Study: 6130558

Group type: EXPERIMENTAL
Intervention: 20 mg clobazam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study: 31764011

Group type: EXPERIMENTAL
Intervention: Inflationary NIBP measurement + cuff (YP‐71xT series)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Deflationary NIBP measurement + conventional cuff (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deflationary NIBP measurement + cuff (YP‐71xT series)
Number of subjects: 30
Study: 29510352

Group type: EXPERIMENTAL
Intervention: affron® (saffron extract), 14 mg b.i.d
Number of subjects: 80
Study: 27170466

Group type: EXPERIMENTAL
Intervention: Estradiol (1 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 24996648

Group type: EXPERIMENTAL
Intervention: Superion interspinous spacer (Experimental)
Number of subjects: 250

Group type: COMPARATOR
Intervention: X-Stop interspinous spacer (Control)
Number of subjects: 250
Study: 22045100

Group type: EXPERIMENTAL
Intervention: NEPP regimen (Nutrineal×1, Extraneal×1, Physioneal×2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: sPD regimen (conventional lactate‐buffered PDF)
Number of subjects: 45
Study: 20538370

Group type: EXPERIMENTAL
Intervention: Web-based didactics
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Classroom-based teaching
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study: 18711963

Group type: EXPERIMENTAL
Intervention: Tension free vaginal tape (TVT)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Transobturator suburethral tape (TVT O)
Number of subjects: 288
Study: 16364834

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg, slow-release pill, administered 1 hour before bed for 3 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (administered for 3 weeks)
Number of subjects: 18
Study: 12055812

Group type: EXPERIMENTAL
Intervention: Combination of ivermectin (150-200 micrograms/kg bodyweight) and albendazole (400 mg)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153

Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ivermectin
Number of subjects: 153

Group type: COMPARATOR
Intervention: Combination of albendazole and ivermectin
Number of subjects: 153
Study: 9872876

Group type: EXPERIMENTAL
Intervention: Migraine (personal history)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Classical migraine (with aura)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Simple migraine (without aura)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Family history of migraine
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Migraine with coexistent oral contraceptive use, high blood pressure, or smoking
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Migraine in women of childbearing age
Number of subjects: 291
Study: 7726443

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Face mask (FM)
Number of subjects: 55
Study: 2325960

Group type: EXPERIMENTAL
Intervention: Hourly oxytocin infusion protocol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Quarter-hourly oxytocin infusion protocol
Number of subjects: 52
Study: 7404129

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with primary hyperparathyroidism
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients on chronic haemodialysis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with hypoparathyroidism
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with malignant disease
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gut hormones (gastrin, secretin, CCK-PK)
Number of subjects: 50
Study: 6363382

Group type: EXPERIMENTAL
Intervention: tobramycin + cefuroxime
Number of subjects: 21

Group type: COMPARATOR
Intervention: tobramycin + penicillin G
Number of subjects: 21
Study: 29680656

Group type: COMPARATOR
Intervention: Candida tropicalis added at 1 g/calf per day (CT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mulberry leaf flavonoids added at 3 g/calf per day (MLF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 15
Study: 27307271

Group type: EXPERIMENTAL
Intervention: Neck collar (n=32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 62
Study: 24115129

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg/week
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 324
Study: 23122801

Group type: EXPERIMENTAL
Intervention: Procedural myocardial infarction (MI) defined by CK-MB elevation of more than 3 times the upper limit of normal (ULN)
Number of subjects: 9087

Group type: EXPERIMENTAL
Intervention: Spontaneous myocardial infarction (MI) defined by CK-MB more than twice the ULN
Number of subjects: 9087

Group type: EXPERIMENTAL
Intervention: Procedural MI with CK-MB threshold of 27.7 times the ULN
Number of subjects: 9087

Group type: EXPERIMENTAL
Intervention: Procedural MI in the SYNERGY study
Number of subjects: 9087

Group type: EXPERIMENTAL
Intervention: Procedural MI in the EARLY-ACS study
Number of subjects: 9087
Study: 20352167

Group type: EXPERIMENTAL
Intervention: Abnormal D-dimer
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Normal D-dimer
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 608
Study: 18599164

Group type: EXPERIMENTAL
Intervention: Two doses of 30 microg or 45 microg H5 HA adjuvanted formulations
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Two doses of 7.5 microg or 15 microg H5 HA (+/- AlPO4 adjuvant)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Booster dose offered 6 months after dose 2 (phase I trial only)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Prototype H5N1 vaccine
Number of subjects: 800
Study: 16078599

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/day for 12 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with DM1 and DN
Number of subjects: 60
Study: 12410741

Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Body mass index and professional education
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 882